Topics

Executive Vice President at Founder Shield.


Articles

Why startups and life sciences companies should approach this booming sector with extreme caution.

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Videos

In the first part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, lays out the systemic gaps in medical and pharmacy education that need to be addressed, along with how academic and clinical institutions can accelerate awareness training in identifying substandard and falsified medicines.

Why Medical Education Must Catch Up 

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

Beyond the Brand Team: Why Every Employee Needs to Be Part of the Journey

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

Multi-Indication Drug Branding in Today’s Pharmaceutical Industry

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one. 

The Tariff Effect: Greater Supply Chain Prepares for Repercussions 

Direct-to-consumer and direct-to-patient models are major contributors. 

Why CX Is a Difference Maker for Pharma

This serialization system represents a business imperative that yields significant competitive advantages.

Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National Community Pharmacists Association (NCPA), discusses pending legislation that could affect the impact of PBM pricing. 

Limiting the Use of Spread Pricing

A Day 3 presentation dives into the impact of copay accumulators, maximizers, and AFPs on driving cost savings. 

Opinion